In conclusion, here we provide further evidence on the efficacy of specifically targeting sFasL in pemphigus and propose PC111 as a potential non-immunosuppressive treatment for this severe and life-threatening disease, opening the way to further development of this approach in clinical settings. This evidence concerns the gene FASLG and pemphigus.